Success Metrics

Clinical Success Rate
72.2%

Based on 13 completed trials

Completion Rate
72%(13/18)
Active Trials
0(0%)
Results Posted
54%(7 trials)
Terminated
5(28%)

Phase Distribution

Ph phase_4
1
6%
Ph phase_2
13
72%
Ph phase_1
2
11%
Ph phase_3
1
6%

Phase Distribution

2

Early Stage

13

Mid Stage

2

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
2(11.8%)
Phase 2Efficacy & side effects
13(76.5%)
Phase 3Large-scale testing
1(5.9%)
Phase 4Post-market surveillance
1(5.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.2%

13 of 18 finished

Non-Completion Rate

27.8%

5 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(13)
Terminated(5)

Detailed Status

Completed13
Terminated5

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
72.2%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (11.8%)
Phase 213 (76.5%)
Phase 31 (5.9%)
Phase 41 (5.9%)

Trials by Status

completed1372%
terminated528%

Recent Activity

0 active trials
Showing 5 of 18
terminatedphase_1

Study of Temzolomide and Gleevec in Advanced Melanoma

NCT00667953
terminatedphase_2

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

NCT00230334
terminatedphase_2

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

NCT00038649
completedphase_2

A Study of Imatinib and Docetaxel in Prostate Cancer

NCT00251225
completedphase_1

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas

NCT01140360
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT00667953Phase 1

Study of Temzolomide and Gleevec in Advanced Melanoma

Terminated
NCT00230334Phase 2

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

Terminated
NCT00038649Phase 2

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Terminated
NCT00251225Phase 2

A Study of Imatinib and Docetaxel in Prostate Cancer

Completed
NCT01140360Phase 1

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas

Completed
NCT00050531Phase 3

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Completed
NCT01092741Phase 2

Late Chronic Phase Chronic Myelogenous Leukemia

Completed
NCT01673009Phase 2

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Completed
NCT00048672Phase 2

Therapy of Early Chronic Phase CML With Gleevec

Completed
NCT00583115Phase 2

Safety Study of Gleevec® in Children With Pulmonary Hypertension

Terminated
NCT01289054

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

Completed
NCT00955916Phase 2

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Completed
NCT00248482Phase 2

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed
NCT00451997Phase 2

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Completed
NCT00156286Phase 2

Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

Completed
NCT01120821Phase 2

Treatment of Polycythemia Vera With Gleevec

Completed
NCT00081926Phase 4

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Completed
NCT00180830Phase 2

Glivec Phase II Pediatric Study

Terminated

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18